Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer

• Identification of proteomic profiles and molecular pathways involved in tumor progression [ Time Frame: After collection of tissue samples ] [ Designated as safety issue: No ]
  Genomic analysis, targeted gene mutation analysis, immunohistochemistry, and mass spectrometry will be employed to identify proteomic profiles and specific molecular pathways involved in tumor progression of fibrolamellar carcinoma and hepatocellular carcinoma
  
  

• Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features [ Time Frame: After molecular analysis of tissue and after collection of clinicopathologic data ] [ Designated as safety issue: No ]
  Compare and contrast fibrolamellar carcinoma with hepatocellular carcinoma in terms of the molecular differences, tissue pathologies, and medical histories.
  
  

Genetic: comparative genomic hybridization
Not specified
Other Name: None specified
Genetic: molecular genetic technique
Not specified
Other Name: none noted
Genetic: mutation analysis
Not specified
Other Name: none noted
Genetic: polymerase chain reaction
Not noted
Other Name: none specified
Genetic: proteomic profiling
not specified
Other Name: none noted
Other: immunohistochemistry staining method
not noted
Other Name: none specified
Other: laboratory biomarker analysis
not noted
Other Name: none specified
Other: mass spectrometry
not noted
Other Name: none specified
Other: medical chart review
not noted
Other Name: none specified

OBJECTIVES:

• To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex.
• To perform genomic analysis on these tissue samples using array comparative genomic hybridization.
• To perform targeted gene mutation analysis on these samples by PCR.
• To perform proteomic profiling on fixed tissues in these samples by various proteomic methods, including IHC and mass spectrometry.
• To look for association between molecular aberrations and clinicopathologic features in these samples.

OUTLINE: Archived tissue samples are collected from the pathology department at Vanderbilt University Medical Center and from the Mayo Clinic in Rochester, Minnesota. Tissue samples are analyzed by genomic analysis using array comparative genomic hybridization, target gene mutation analysis by PCR, and proteomic profiling on fixed tissues using various proteomic methods, including IHC and mass spectrometry. Samples are also examined for association between molecular aberrations and clinicopathologic features found in each disease.

Clinical patient data (i.e., age, sex, race, date of diagnosis, risk factors, histology, surgical staging, follow-ups, date of death, and adjuvant therapy) are also collected.